Home › Trials › NCT06215118

Effects of Elranatamab and Iberdomide in Patients with Multiple Myeloma

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Phase 1 Interventional Pfizer · NCT06215118

This study is testing a new combination of two medications, elranatamab and iberdomide, to see if they are safe and effective for people with multiple myeloma who have not responded to other treatments.

Quick facts

PhasePhase 1
Study typeInterventional
Enrollment87 (estimated)
Ages18 Years and up
SexAll
SponsorPfizer Industry-sponsored
Drugs / interventionselranatamab
Locations21 sites (Deerfield Beach, Florida and 20 other locations)
Trial IDNCT06215118 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the safety and tolerability of elranatamab when combined with iberdomide in patients with relapsed or refractory multiple myeloma. It consists of two parts: the first part assesses the safety and tolerability of the combination, while the second part determines the optimal dosage for patients. Participants will receive elranatamab via subcutaneous injection and iberdomide orally over 28-day cycles until disease progression, unacceptable side effects, or withdrawal from the study. The study focuses on patients who have previously undergone multiple lines of therapy for their condition.

Who should consider this trial

Good fit: Ideal candidates are adults with a prior diagnosis of multiple myeloma who have received multiple lines of therapy and have measurable disease.

Not a fit: Patients with plasma cell leukemia, smoldering multiple myeloma, or other specified conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this combination therapy could provide a new treatment option for patients with relapsed or refractory multiple myeloma.

How similar studies have performed: Other studies have shown promise with similar combination therapies in treating multiple myeloma, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Prior diagnosis of multiple myeloma as defined by IMWG criteria
* Measurable disease based on IMWG criteria as defined by at least 1 of the following:
* Serum M-protein ≥0.5 g/dL by SPEP
* Urinary M-protein excretion ≥200 mg/24 hour by UPEP
* Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (\<0.26 or \>1.65)
* Part 1: Received 2-4 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.
* Part 2: Received 1-3 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.
* ECOG performance status 0-1
* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1

Exclusion Criteria:

* Plasma cell leukemia, Smoldering multiple myeloma, Waldenström's macroglobulinemia, Amyloidosis, POEMS Syndrome
* Impaired cardiovascular function or clinically significant cardiovascular diseases
* Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease
* Participants with any active, uncontrolled bacterial, fungal, or viral infection
* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
* Previous treatment with:
* BCMA-directed or CD3 redirecting therapy
* Iberdomide (CC-220) or Mezigdomide
* Administration of strong inhibitor or inducer of CYP3A4/5 within 2 weeks prior to dosing and during the study
* Administration with an investigational product within 30 days preceding the first dose of study intervention
* Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis

Where this trial is running

Deerfield Beach, Florida and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaelranatamabPF-06863135iberdomiderelapsedrefractoryRRMMBCMA
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.